Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pediatric PNH - Diagnosis and Treatment

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Satheesh Chonat, MD
In this webinar, Dr. Satheesh Chonat will discuss what is PNH, how PNH is diagnosed and what treatment options are available to pediatric patients. After the presentation, Dr. Chonat will answer questions from participants. Advance questions can be submitted to help@aamds.org.

Satheesh Chonat, MD

Institution
Children’s Healthcare of Atlanta
Physician Status
available for consultation
Primary Disease Area of Focus
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Satheesh Chonat, MD, is a Pediatric Hematologist and Oncologist at Children’s Healthcare of Atlanta and board-certified in pediatrics and pediatric hematology/oncology. He specializes in the care of children and young adults with nonmalignant rare blood disorders by using a variety of clinical and research-based tools. Dr. Chonat is the site investigator for various clinical and translational research projects, focused on rare red blood disorders, such as pyruvate kinase disease, thrombotic thrombocytopenic purpura and paroxysmal nocturnal hemoglobinuria. The main focus of his laboratory

Clinical Trials and Children

Until recently, children were rarely included in studies of medical treatments. As a result, much is still unknown about how children respond to drugs, some biologics (such as gene therapy) and medical devices. According to the U.S. Food and Drug Administration (FDA), only 20-30% of approved drugs have actually been labeled for use in children.

mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

Original Publication Date
Article Source
External Web Content
The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines…

Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH

Original Publication Date
Article Source
External Web Content
Published: Dec 15, 2021 STOCKHOLM, Dec. 15, 2021 /PRNewswire/ -- The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels1 Aspaveli will…

BCX9930

is an oral small molecule inhibitor
Subscribe to Paroxysmal Nocturnal Hemoglobinuria (PNH)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.